Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

J. M. Nabholtz, K. Gelmon, M. Bontenbal, M. Spielmann, G. Catimel, P. Conte, U. Klaassen, M. Namer, J. Bonneterre, P. Fumoleau, B. Winograd

Research output: Contribution to journalArticle

370 Citations (Scopus)

Abstract

Purpose and Methods: The objective of this multicenter study was to compare the therapeutic index of two different doses of paclitaxel given as a 3-hour infusion in patients with metastatic breast cancer (MBC), who had failed to respond to previous chemotherapy. A total of 471 patients with MBC were randomized to receive intravenous paclitaxel at a dose of 175 or 135 mg/m2 every 3 weeks. Results: Better treatment results were achieved with high-dose (HD) versus low-dose (LD) paclitaxel: overall response rate, 29% versus 22% (P =. 108); complete response (CR) rate, 5% versus 2% (P = .088); median time to disease progression, 4.2 versus 3.0 months (P = .027); and median survival time, 11.7 versus 10.5 months (P = .321). Patients previously exposed or resistant to anthracyclines were as likely to respond as those without such prior exposure. Treatment was well tolerated, as documented by the number of administered treatment courses (median, six v five; range, one to 17 v one to 18), the low frequency of dose reductions (14% v 7%, P = .024), and the small number of patients (n = 9 or 4% v n = 5 or 2%) who required treatment discontinuation for adverse reactions. The incidence and severity of neutropenia and peripheral neuropathy were dose-related. After quality-of-life-adjusted time-to-progression analysis, the HD arm (175 mg/m2) retained its advantage over the LD arm (135 mg/m2). Conclusion: The results of this trial substantiate the activity of paclitaxel in the treatment of MBC. The observed superior efficacy with a dose of 175 mg/m2 over 135 mg/m2 suggests a dose-effect relationship. The clinical activity in anthracycline-resistant patients is particularly noteworthy. Paclitaxel in breast cancer needs further evaluation in large trials that use combination chemotherapy and involve earlier disease stages.

Original languageEnglish
Pages (from-to)1858-1867
Number of pages10
JournalJournal of Clinical Oncology
Volume14
Issue number6
Publication statusPublished - Jun 1996

Fingerprint

Paclitaxel
Breast Neoplasms
Anthracyclines
Therapeutics
Peripheral Nervous System Diseases
Combination Drug Therapy
Neutropenia
Multicenter Studies
Disease Progression
Quality of Life
Drug Therapy
Survival
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nabholtz, J. M., Gelmon, K., Bontenbal, M., Spielmann, M., Catimel, G., Conte, P., ... Winograd, B. (1996). Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. Journal of Clinical Oncology, 14(6), 1858-1867.

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. / Nabholtz, J. M.; Gelmon, K.; Bontenbal, M.; Spielmann, M.; Catimel, G.; Conte, P.; Klaassen, U.; Namer, M.; Bonneterre, J.; Fumoleau, P.; Winograd, B.

In: Journal of Clinical Oncology, Vol. 14, No. 6, 06.1996, p. 1858-1867.

Research output: Contribution to journalArticle

Nabholtz, JM, Gelmon, K, Bontenbal, M, Spielmann, M, Catimel, G, Conte, P, Klaassen, U, Namer, M, Bonneterre, J, Fumoleau, P & Winograd, B 1996, 'Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer', Journal of Clinical Oncology, vol. 14, no. 6, pp. 1858-1867.
Nabholtz, J. M. ; Gelmon, K. ; Bontenbal, M. ; Spielmann, M. ; Catimel, G. ; Conte, P. ; Klaassen, U. ; Namer, M. ; Bonneterre, J. ; Fumoleau, P. ; Winograd, B. / Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. In: Journal of Clinical Oncology. 1996 ; Vol. 14, No. 6. pp. 1858-1867.
@article{aca4249280eb47d7948b3568d5812786,
title = "Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer",
abstract = "Purpose and Methods: The objective of this multicenter study was to compare the therapeutic index of two different doses of paclitaxel given as a 3-hour infusion in patients with metastatic breast cancer (MBC), who had failed to respond to previous chemotherapy. A total of 471 patients with MBC were randomized to receive intravenous paclitaxel at a dose of 175 or 135 mg/m2 every 3 weeks. Results: Better treatment results were achieved with high-dose (HD) versus low-dose (LD) paclitaxel: overall response rate, 29{\%} versus 22{\%} (P =. 108); complete response (CR) rate, 5{\%} versus 2{\%} (P = .088); median time to disease progression, 4.2 versus 3.0 months (P = .027); and median survival time, 11.7 versus 10.5 months (P = .321). Patients previously exposed or resistant to anthracyclines were as likely to respond as those without such prior exposure. Treatment was well tolerated, as documented by the number of administered treatment courses (median, six v five; range, one to 17 v one to 18), the low frequency of dose reductions (14{\%} v 7{\%}, P = .024), and the small number of patients (n = 9 or 4{\%} v n = 5 or 2{\%}) who required treatment discontinuation for adverse reactions. The incidence and severity of neutropenia and peripheral neuropathy were dose-related. After quality-of-life-adjusted time-to-progression analysis, the HD arm (175 mg/m2) retained its advantage over the LD arm (135 mg/m2). Conclusion: The results of this trial substantiate the activity of paclitaxel in the treatment of MBC. The observed superior efficacy with a dose of 175 mg/m2 over 135 mg/m2 suggests a dose-effect relationship. The clinical activity in anthracycline-resistant patients is particularly noteworthy. Paclitaxel in breast cancer needs further evaluation in large trials that use combination chemotherapy and involve earlier disease stages.",
author = "Nabholtz, {J. M.} and K. Gelmon and M. Bontenbal and M. Spielmann and G. Catimel and P. Conte and U. Klaassen and M. Namer and J. Bonneterre and P. Fumoleau and B. Winograd",
year = "1996",
month = "6",
language = "English",
volume = "14",
pages = "1858--1867",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

AU - Nabholtz, J. M.

AU - Gelmon, K.

AU - Bontenbal, M.

AU - Spielmann, M.

AU - Catimel, G.

AU - Conte, P.

AU - Klaassen, U.

AU - Namer, M.

AU - Bonneterre, J.

AU - Fumoleau, P.

AU - Winograd, B.

PY - 1996/6

Y1 - 1996/6

N2 - Purpose and Methods: The objective of this multicenter study was to compare the therapeutic index of two different doses of paclitaxel given as a 3-hour infusion in patients with metastatic breast cancer (MBC), who had failed to respond to previous chemotherapy. A total of 471 patients with MBC were randomized to receive intravenous paclitaxel at a dose of 175 or 135 mg/m2 every 3 weeks. Results: Better treatment results were achieved with high-dose (HD) versus low-dose (LD) paclitaxel: overall response rate, 29% versus 22% (P =. 108); complete response (CR) rate, 5% versus 2% (P = .088); median time to disease progression, 4.2 versus 3.0 months (P = .027); and median survival time, 11.7 versus 10.5 months (P = .321). Patients previously exposed or resistant to anthracyclines were as likely to respond as those without such prior exposure. Treatment was well tolerated, as documented by the number of administered treatment courses (median, six v five; range, one to 17 v one to 18), the low frequency of dose reductions (14% v 7%, P = .024), and the small number of patients (n = 9 or 4% v n = 5 or 2%) who required treatment discontinuation for adverse reactions. The incidence and severity of neutropenia and peripheral neuropathy were dose-related. After quality-of-life-adjusted time-to-progression analysis, the HD arm (175 mg/m2) retained its advantage over the LD arm (135 mg/m2). Conclusion: The results of this trial substantiate the activity of paclitaxel in the treatment of MBC. The observed superior efficacy with a dose of 175 mg/m2 over 135 mg/m2 suggests a dose-effect relationship. The clinical activity in anthracycline-resistant patients is particularly noteworthy. Paclitaxel in breast cancer needs further evaluation in large trials that use combination chemotherapy and involve earlier disease stages.

AB - Purpose and Methods: The objective of this multicenter study was to compare the therapeutic index of two different doses of paclitaxel given as a 3-hour infusion in patients with metastatic breast cancer (MBC), who had failed to respond to previous chemotherapy. A total of 471 patients with MBC were randomized to receive intravenous paclitaxel at a dose of 175 or 135 mg/m2 every 3 weeks. Results: Better treatment results were achieved with high-dose (HD) versus low-dose (LD) paclitaxel: overall response rate, 29% versus 22% (P =. 108); complete response (CR) rate, 5% versus 2% (P = .088); median time to disease progression, 4.2 versus 3.0 months (P = .027); and median survival time, 11.7 versus 10.5 months (P = .321). Patients previously exposed or resistant to anthracyclines were as likely to respond as those without such prior exposure. Treatment was well tolerated, as documented by the number of administered treatment courses (median, six v five; range, one to 17 v one to 18), the low frequency of dose reductions (14% v 7%, P = .024), and the small number of patients (n = 9 or 4% v n = 5 or 2%) who required treatment discontinuation for adverse reactions. The incidence and severity of neutropenia and peripheral neuropathy were dose-related. After quality-of-life-adjusted time-to-progression analysis, the HD arm (175 mg/m2) retained its advantage over the LD arm (135 mg/m2). Conclusion: The results of this trial substantiate the activity of paclitaxel in the treatment of MBC. The observed superior efficacy with a dose of 175 mg/m2 over 135 mg/m2 suggests a dose-effect relationship. The clinical activity in anthracycline-resistant patients is particularly noteworthy. Paclitaxel in breast cancer needs further evaluation in large trials that use combination chemotherapy and involve earlier disease stages.

UR - http://www.scopus.com/inward/record.url?scp=8944245005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8944245005&partnerID=8YFLogxK

M3 - Article

C2 - 8656254

AN - SCOPUS:8944245005

VL - 14

SP - 1858

EP - 1867

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -